Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Rafael De La Barrera"'
Autor:
Marcia da Costa Castilho, Ana Maria Bispo de Filippis, Lais Ceschini Machado, Thaise Yasmine Vasconcelos de Lima Calvanti, Morganna Costa Lima, Vagner Fonseca, Marta Giovanetti, Cassia Docena, Armando Menezes Neto, Camila Helena Aguiar Bôtto-Menezes, Edna Oliveira Kara, Rafael de La Barrera, Kayvon Modjarrad, Silvana Pereira Giozza, Gerson Fernando Pereira, Luiz Carlos Junior Alcantara, Nathalie Jeanne Nicole Broutet, Guilherme Amaral Calvet, Gabriel Luz Wallau, Rafael Freitas Oliveira Franca
Publikováno v:
Emerging Infectious Diseases, Vol 30, Iss 2, Pp 310-320 (2024)
We generated 238 Zika virus (ZIKV) genomes from 135 persons in Brazil who had samples collected over 1 year to evaluate virus persistence. Phylogenetic inference clustered the genomes together with previously reported ZIKV strains from northern Brazi
Externí odkaz:
https://doaj.org/article/bff984d47f3a49eabb7a3b59b04456f6
Autor:
Kathryn McGuckin Wuertz, Erica K. Barkei, Wei-Hung Chen, Elizabeth J. Martinez, Ines Lakhal-Naouar, Linda L. Jagodzinski, Dominic Paquin-Proulx, Gregory D. Gromowski, Isabella Swafford, Akshaya Ganesh, Ming Dong, Xiankun Zeng, Paul V. Thomas, Rajeshwer S. Sankhala, Agnes Hajduczki, Caroline E. Peterson, Caitlin Kuklis, Sandrine Soman, Lindsay Wieczorek, Michelle Zemil, Alexander Anderson, Janice Darden, Heather Hernandez, Hannah Grove, Vincent Dussupt, Holly Hack, Rafael de la Barrera, Stasya Zarling, James F. Wood, Jeffrey W. Froude, Matthew Gagne, Amy R. Henry, Elham Bayat Mokhtari, Prakriti Mudvari, Shelly J. Krebs, Andrew S. Pekosz, Jeffrey R. Currier, Swagata Kar, Maciel Porto, Adrienne Winn, Kamil Radzyminski, Mark G. Lewis, Sandhya Vasan, Mehul Suthar, Victoria R. Polonis, Gary R. Matyas, Eli A. Boritz, Daniel C. Douek, Robert A. Seder, Sharon P. Daye, Mangala Rao, Sheila A. Peel, M. Gordon Joyce, Diane L. Bolton, Nelson L. Michael, Kayvon Modjarrad
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-11 (2021)
Abstract The emergence of SARS-CoV-2 variants of concern (VOC) requires adequate coverage of vaccine protection. We evaluated whether a SARS-CoV-2 spike ferritin nanoparticle vaccine (SpFN), adjuvanted with the Army Liposomal Formulation QS21 (ALFQ),
Externí odkaz:
https://doaj.org/article/3d4762c8ae9d4d3e8004ffeb07a8b88e
Autor:
Michael K. McCracken, Caitlin H. Kuklis, Chandrika B. Kannadka, David A. Barvir, Mark A. Sanborn, Adam T. Waickman, Hayden C. Siegfried, Kaitlin A. Victor, Kristin L. Hatch, Rafael De La Barrera, Shannon D. Walls, Wiriya Rutvisuttinunt, Jeffrey R. Currier, Heather Friberg, Richard G. Jarman, Gregory D. Gromowski
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-12 (2021)
Abstract Antibody-dependent enhancement (ADE) is suspected to influence dengue virus (DENV) infection, but the role ADE plays in vaccination strategies incorporating live attenuated virus components is less clear. Using a heterologous prime-boost str
Externí odkaz:
https://doaj.org/article/d8ee938ae9d948e0b132ccac35634eaa
Autor:
Michael K McCracken, Gregory D Gromowski, Heather L Friberg, Xiaoxu Lin, Peter Abbink, Rafael De La Barrera, Kenneth H Eckles, Lindsey S Garver, Michael Boyd, David Jetton, Dan H Barouch, Matthew C Wise, Bridget S Lewis, Jeffrey R Currier, Kayvon Modjarrad, Mark Milazzo, Michelle Liu, Anna B Mullins, J Robert Putnak, Nelson L Michael, Richard G Jarman, Stephen J Thomas
Publikováno v:
PLoS Pathogens, Vol 13, Iss 8, p e1006487 (2017)
Studies have demonstrated cross-reactivity of anti-dengue virus (DENV) antibodies in human sera against Zika virus (ZIKV), promoting increased ZIKV infection in vitro. However, the correlation between in vitro and in vivo findings is not well charact
Externí odkaz:
https://doaj.org/article/60a145e92db048278177d0a157c5894e
Autor:
Sandrine Soman, Shelly J. Krebs, Diane L. Bolton, Gregory D. Gromowski, Ines Lakhal-Naouar, Swagata Kar, Michelle Zemil, Linda L. Jagodzinski, Amy R. Henry, Robert A. Seder, Lindsay Wieczorek, Hannah Grove, Dominic Paquin-Proulx, Adrienne Winn, Daniel C. Douek, Holly R. Hack, Caitlin Kuklis, Kamil Radzyminski, Rafael De La Barrera, Matthew Gagne, Caroline E. Peterson, James F. Wood, Heather Hernandez, Alexander R. A. Anderson, Xiankun Zeng, Stasya Zarling, Wei-Hung Chen, Mark G. Lewis, Rajeshwer S. Sankhala, Prakriti Mudvari, Andrew Pekosz, Victoria R. Polonis, Maciel Porto, Mangala Rao, Paul V. Thomas, Eli Boritz, M. Gordon Joyce, Sheila A. Peel, Elham Bayat Mokhtari, Kathryn McGuckin Wuertz, Nelson L. Michael, Sharon P. Daye, Akshaya Ganesh, Agnes Hajduczki, Gary R. Matyas, Jeffrey W. Froude, Vincent Dussupt, Erica K. Barkei, Kayvon Modjarrad, Jeffrey R. Currier, Sandhya Vasan, Janice Darden, Isabella Swafford, Elizabeth J. Martinez, Mehul S. Suthar, Ming Dong
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-11 (2021)
NPJ Vaccines
NPJ Vaccines
The emergence of SARS-CoV-2 variants of concern (VOC) requires adequate coverage of vaccine protection. We evaluated whether a SARS-CoV-2 spike ferritin nanoparticle vaccine (SpFN), adjuvanted with the Army Liposomal Formulation QS21 (ALFQ), conferre
Autor:
Roland Zahn, Carlos Fierro, Maarten Leyssen, Marrit N. Habets, Kayvon Modjarrad, Rafael A. Larocca, Carla Truyers, Hanneke Schuitemaker, Leslie van der Fits, Diane G. Kanjilal, Kristi Lynn Williams, Nadine C. Salisch, Jenny Hendriks, Kathryn E. Stephenson, Macaya Douoguih, Johan Van Hoof, Dan H. Barouch, Conor P. Cahill, Freek Cox, Dirk Heerwegh, Jinyan Liu, Peter Abbink, Lauren Peter, Rafael De La Barrera
Publikováno v:
Annals of Internal Medicine. 174:585-594
BACKGROUND: Zika virus (ZIKV) may cause severe congenital disease after maternal-fetal transmission. No vaccine is currently available. OBJECTIVE: To assess the safety and immunogenicity of Ad26.ZIKV.001, a prophylactic ZIKV vaccine candidate. DESIGN
Autor:
Paul B. Keiser, Michael Koren, Kenneth H. Eckels, Naomi E. Aronson, Jeffrey R. Currier, Erica L Sondergaard, Louis E. Jasper, Leyi Lin, Heather Friberg, Richard G. Jarman, Marvin J Sklar, Rafael De La Barrera, Gregory D. Gromowski, Stephen J. Thomas, Timothy P. Endy, Kristopher M. Paolino
Publikováno v:
The Journal of Infectious Diseases. 223:1707-1716
Background Dengue is a global health problem and the development of a tetravalent dengue vaccine with durable protection is a high priority. A heterologous prime-boost strategy has the advantage of eliciting immune responses through different mechani
Autor:
Jessica L Ansel, Dan H. Barouch, Kayvon Modjarrad, Katherine E. Yanosick, Lauren Peter, Edward T. Moseley, Rafael De La Barrera, Tatenda Makoni, Michael S. Seaman, Peter Dawson, Rachel Fogel, Joseph P. Nkolola, Kathryn E. Stephenson, Stephen R. Walsh, Andrew J. Hale, Diane G. Kanjilal, Kate Jaegle, Nelson L. Michael, Stephen J. Thomas, Connor Bradshaw, Abishek Chandrashekar, Jason Thompson, Kenneth H. Eckels, Erica N. Borducchi, Anna Tyler, Chen S. Tan
Publikováno v:
Lancet Infect Dis
Summary Background The development of an effective vaccine against Zika virus remains a public health priority. A Zika purified inactivated virus (ZPIV) vaccine candidate has been shown to protect animals against Zika virus challenge and to be well t
Autor:
Robert Paris, Maribel Campos, Kenneth H. Eckels, Alexander C. Schmidt, Luis J. Martinez, Richard G. Jarman, Irma Febo, Clemente Diaz, David W. Vaughn, Edith Lepine, Michael Koren, Rafael De La Barrera, Stephen J. Thomas, Todd M. Wilson, Leyi Lin
Publikováno v:
The American Journal of Tropical Medicine and Hygiene
Four formulations of an investigational tetravalent dengue purified inactivated vaccine, administered as two doses one month (M) apart, were previously shown to be immunogenic and well-tolerated up to M13 of the phase I study NCT01702857. Here, we re
Autor:
Philippe Moris, Richard G. Jarman, Edith Lepine, Leyi Lin, Rafael De La Barrera, Heather Friberg, Paul B. Keiser, Monica A. McArthur, Robert Paris, Kenneth H. Eckels, Alexander C. Schmidt, Michael Koren, David W. Vaughn, Stephen J. Thomas, Jeffrey R. Currier, Kirsten E. Lyke
Publikováno v:
The American Journal of Tropical Medicine and Hygiene
Dengue disease and its causative agents, the dengue viruses (DENV-1–4), cause high morbidity in tropical and subtropical regions. We evaluated three dosing regimens of the investigational tetravalent AS03B-adjuvanted dengue-purified inactivated vac